Form 8-K Provention Bio, Inc. For: May 27
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/21/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Far-left party wins Berlin election, pledging to nationalise housing
- Cybercrime feud erupts on dark web as notorious group claims hijack of rival's website
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
Provention Bio Inc. (PRVB) PT Lowered to $22.50 at Chardan Capital Markets Following FDA AdComm Vote
May 28, 2021 9:29 AM EDTChardan Capital Markets analyst Gbola Amusa lowered the price target on Provention Bio Inc. (NASDAQ: PRVB) to $22.50 (from $35.00) while maintaining a Buy rating following the FDA Advisory Committee vote.
The analyst commented, "Provention Bio (Buy): Yesterday, the FDA Advisory Committee (EMDAC)... More
Provention Bio Inc. (PRVB) to Resume Trading at 7:10 a.m.
May 28, 2021 7:08 AM EDTProvention Bio Inc. (NASDAQ: PRVB) to Resume Trading at 7:10 a.m.
